AIXC AIxCrypto Holdings, Inc. logo

AIXC AIxCrypto Holdings, Inc.

Healthcare
$1.29-6.52%ClosedMarket Cap: $6.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

0.45

P/S

0.00

EV/EBITDA

-0.02

DCF Value

$7.69

FCF Yield

-148.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-94.1%

ROA

-85.3%

ROIC

-67.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-6.1M$
Q4 null$0.00$-10.6M$
FY null$0.00$-17.0M$
Q3 null$0.00$-2.0M$

Trading Activity

Insider Trades

View All
Wang Jiaweiofficer: Co-Chief Executive Officer
SellFri Dec 05
Wang Jiaweiofficer: Co-Chief Executive Officer
SellFri Dec 05
FARADAY FUTURE INTELLIGENT ELECTRIC INC.10 percent owner
SellFri Dec 05
FARADAY FUTURE INTELLIGENT ELECTRIC INC.10 percent owner
SellFri Dec 05

Company Info

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Country

US

Exchange

Beta

0.52

AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was formerly known as Qualigen Therapeutics, Inc. and changed its name to AIxCrypto Holdings, Inc. in November 2025. The company was founded in 1996 and is based in Carlsbad, California.

Peers